Physician profile
Ruth E Gonzalez
NPI 1659399087
$11,080.87
in general payments reported to CMS, 2019-2025
26 companies · $1,134 in 2025
The $1,134 reported for 2025 was more than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,117 · 2020: $2,069 · 2021: $1,968 · 2022: $1,369 · 2023: $1,436 · 2024: $987 · 2025: $1,134.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,557.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,557.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,866.41 | 2019-2025 | |
| Ucb, INC. | $1,983.93 | 2019-2025 | Cimzia, Bimzelx |
| E.R. Squibb & Sons, L.L.C. | $1,121.80 | 2019-2022 | |
| Glaxosmithkline, LLC. | $810.28 | 2019-2023 | Benlysta |
| Lilly USA, LLC | $655.21 | 2019-2024 | Taltz |
| Pfizer INC. | $622.69 | 2019-2025 | |
| Amgen INC. | $618.93 | 2019-2025 | Evenity, Enbrel, Prolia |
| Mallinckrodt Hospital Products INC. | $438.22 | 2020-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $263.64 | 2019-2022 | |
| Genzyme Corporation | $244.64 | 2019-2025 | |
| Mallinckrodt Enterprises LLC | $221.73 | 2019 | |
| Genentech USA, INC. | $180.26 | 2019-2020 | |
| Revance Therapeutics, INC. | $162.20 | 2024 | Daxxify |
| Sobi, INC | $132.95 | 2020-2025 | |
| Novartis Pharmaceuticals Corporation | $114.94 | 2021-2025 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ani Pharmaceuticals, INC. | $104.90 | 2022-2023 | Purified Cortrophin Gel |
| Horizon Therapeutics Plc | $95.90 | 2019 | |
| Janssen Biotech, INC. | $92.00 | 2019-2022 | |
| Radius Health, INC. | $88.20 | 2019-2025 | Tymlos |
| Astrazeneca Pharmaceuticals LP | $73.51 | 2021-2022 | |
| Tersera Therapeutics LLC | $56.92 | 2025 | Quzyttir |
| Novo Nordisk INC | $49.37 | 2025 | Wegovy |
| Fresenius Kabi USA, LLC | $34.40 | 2023 | Idacio |
| Ultragenyx Pharmaceutical INC. | $19.04 | 2021 | |
| Ibsa Pharma INC. | $15.00 | 2020 | |
| Depuy Synthes Sales INC. | $13.80 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ruth Gonzalez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.